Search results
Results from the WOW.Com Content Network
The biotech industry has lagged the broader market so far in 2024. Despite moving in opposite directions in 2024, CRISPR Therapeutics and Exelixis have strong prospects. CRISPR Therapeutics is a ...
In the third quarter, the company's revenue of $2.77 billion increased by 12% year over year, a strong performance for a biotech giant. The company's best CF treatment yet, Trikafta, accounted for ...
For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry. Unlike companies that build up their businesses over time at a steadier pace ...
With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an impressive resume already, but it's just getting started. It's currently in the ...
What biotech stock did Warren Buffett buy? In 2019, Warren Buffett's investment firm Berkshire Hathaway purchased biotech stocks for the first time. The firm purchased more than 648,000 shares of ...
For investors seeking a strong growth option, and willing to take on some added risk, the biotech sector offers an unparalleled opportunity. Unlike other names, biotech companies often rely on ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that ...
For investors seeking strong returns, few market sectors can offer the high potential found in biotech. It doesn’t come easy, though. Biotech firms are notorious for running losses. The lead ...